31st week of 2015 patent applcation highlights part 22 |
Patent application number | Title | Published |
20150210672 | ORGANIC COMPOUNDS - The present invention provides novel organic compounds of Formula (I): methods of use, and pharmaceutical compositions thereof. | 2015-07-30 |
20150210674 | SMALL MOLECULE ACTIVATORS OF MITOCHONDRIAL FUNCTION - Methods for improving mitochondrial function, decreasing iron accumulation, and/or decreasing oxidative stress by exposing cells or treating a subject to compounds or compositions of the general formula | 2015-07-30 |
20150210675 | LONG CHAIN BASE SPHINGOSINE KINASE INHIBITORS - The invention relates to inhibitors of Sphingosine Kinase enzymatic activity, and methods of treating diseases and disorders by administering inhibitors of Sphingosine Kinase enzymatic activity. | 2015-07-30 |
20150210676 | TRICYCLIC AMIDINE DERIVATIVES AS HIV ATTACHMENT INHIBITORS - Compounds of Formula I, including pharmaceutically acceptable salts thereof: (F) wherein A is selected from the group consisting of: (F) and; (F) and wherein Z is: (F) are useful as HIV attachment inhibitors. | 2015-07-30 |
20150210677 | Inhibitors of Beta-Hydroxylase for Treatment of Cancer - The present invention relates to compounds which modulate (e.g., inhibit) the activity of beta-hydroxylase (e.g., Asparatyl (asparaginyl) β-hydroxylase (ASPH)), including novel 2-aryl-5-amino-3(2H)-furanone and 2-heteroaryl-5-amino-3(2H)-furanone compounds, pharmaceutical compositions thereof, methods for their synthesis, and methods of using these compounds to modulate the activity of ASPH in an a cell-free sample, a cell-based assay, and in a subject. Other aspects of the invention relate to use of the compounds disclosed herein to ameliorate or treat cell proliferation disorders. | 2015-07-30 |
20150210678 | N-CYCLOALKYL-N-[(HETEROCYCLYLPHENYL)METHYLENE]-(THIO)CARBOXAMIDE DERIVATIVES - The present invention relates to fungicidal N-cycloalkyl-N-[(heterocyclylphenyl)methylene]carboxamide derivatives and their thiocarbonyl derivatives, their process of preparation and intermediate compounds for their preparation, their use as fungicides, particularly in the form of fungicidal compositions and methods for the control of phytopathogenic fungi of plants using these compounds or their compositions. | 2015-07-30 |
20150210679 | SMALL MOLECULE INHIBITORS OF SUPEROXIDE DISMUTASE EXPRESSION - Disclosed are new small molecules and the uses thereof for inhibiting superoxide dismutase (SOD) expression. Also disclosed are pharmaceutical compositions comprising the small molecule inhibitors which may be administered in methods of treating diseases or disorders associated with elevated SOD expression or activity, including neurological diseases and disorders such as amyotrophic lateral sclerosis (ALS). | 2015-07-30 |
20150210680 | AMINODIHYDROTHIAZINE DERIVATIVES - A composition having BACE 1 inhibitory activity containing a compound represented by the general formula (I): | 2015-07-30 |
20150210681 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS - The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, cystic disease and for the treatment of cancer. | 2015-07-30 |
20150210682 | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection - The invention provides novel compounds having the general formula: | 2015-07-30 |
20150210683 | SUBSTITUTED TRIAZOLOPYRIDINES AND THEIR USE AS TTK INHIBITORS - The present invention relates to substituted triazolopyridine compounds of general formula (I): | 2015-07-30 |
20150210684 | PIPERIDINE AMIDE DERIVATIVES AS HIV ATTACHMENT INHIBITORS - Compounds of Formula I, including pharmaceutically acceptable salts thereof: formule (I): wherein A is selected from the group consisting of: formule (II) and wherein Z is selected from the group consisting of: formule (III): and. are useful as HIV attachment inhibitors. | 2015-07-30 |
20150210685 | NOVEL AZABENZIMIDAZOLE TETRAHYDROPYRAN DERIVATIVES - Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPKactivated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension. | 2015-07-30 |
20150210686 | (AZA-)ISOQUINOLINONE DERIVATIVES - Compounds of the formula I | 2015-07-30 |
20150210687 | N-ALKYLATED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF - The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts or solvates thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions. | 2015-07-30 |
20150210688 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS - Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by disregulation of a fatty acid synthase pathway by the administration of such compounds. | 2015-07-30 |
20150210689 | ANTAGONISTS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS FOR THE TREATMENT OF INFLAMMATION - Compounds, processes for their preparation, pharmaceutical compositions containing such compounds and their use in treating therapeutic conditions, in particular conditions mediated by the action of ligands on the FP, DP, EP | 2015-07-30 |
20150210690 | NEPRILYSIN INHIBITORS - In one aspect, the invention relates to compounds having the formula I: | 2015-07-30 |
20150210691 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS - The present application describes lactam-containing compounds and derivatives thereof of Formula I: | 2015-07-30 |
20150210692 | Spirocycles as Inhibitors of 11-beta Hydroxyl Steroid Dehydrogenase Type 1 - The present invention relates to certain spirocyclic compounds that are inhibitors of 11-β hydroxyl steroid dehydrogenase type 1 (11βHSD1), compositions containing the same, and methods of using the same for the treatment of diabetes, obesity and other diseases. | 2015-07-30 |
20150210693 | HYDROCHLORIDE SALTS OF 8-[1-(3,5-BIS-(TRIFLUOROMETHYL)PHENYL)-ETHOXYMETHYL]-8-PHENYL-1,7-DIAZASP- IRO[4,5]DECAN-2-ONE AND PREPARATION PROCESS THEREFOR - Disclosed are hydrochloride and tosylate crystalline salt forms of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula 1 and methods of preparing the same. | 2015-07-30 |
20150210694 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR - Described herein are inhibitors of FGFR, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of tyrosine kinases. | 2015-07-30 |
20150210695 | COMPOSITIONS COMPRISING FOLIC ACID DERIVATIVES, THEIR PREPARATIONS AND METHODS OF USE - Described herein are methods for making folic acid derivatives, intermediates, pharmaceutical compositions and uses thereof. | 2015-07-30 |
20150210696 | PROTEIN KINASE INHIBITORS - The present invention relates to novel kinase inhibitors. Compounds of this class have been found to be effective inhibitors of protein kinases; including members of PDGFR and VEGFR families. | 2015-07-30 |
20150210697 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS - The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazotriazines inhibit protein kinase activity thereby making them useful as anticancer agents. | 2015-07-30 |
20150210698 | AGENT FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA - This invention relates to an agent for treating or inhibiting recurrence of acute myeloid leukemia and an agent for inhibiting growth of leukemia stem cells comprising a compound represented by formula (I) or a salt thereof: | 2015-07-30 |
20150210699 | Deuterated Ibrutinib - The present invention in one embodiment provides a compound of Formula (I); or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula (I) are as defined in the specification. | 2015-07-30 |
20150210700 | INDOLE-SUBSTITUTED PYRROLOPYRIMIDINYL INHIBITORS OF UBA6 - Disclosed are chemical entities that inhibit Uba6, each of which is a compound of Formula /: Formula (I) or a pharmaceutically acceptable salt thereof, wherein R* | 2015-07-30 |
20150210701 | TREATMENT OF HELICOBACTER PYLORI INFECTIONS - Methods of treating infections due to | 2015-07-30 |
20150210702 | NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES - The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of proliferation disorders and other diseases related to the dysregulation of kinase (such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3(D835Y), ITK, JAK1, JAK2, JAK3, TEC and TXK) and/or the respective pathways. | 2015-07-30 |
20150210703 | IMIDAZOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES - The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases. | 2015-07-30 |
20150210704 | INHIBITORS OF BRUTON'S TYROSINE KINASE - This application discloses compounds according to generic Formula I: wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient. | 2015-07-30 |
20150210705 | SUBSTITUTED PYRROLOPYRIDINES AND PYRROLOPYRAZINES FOR TREATING CANCER OR INFLAMMATORY DISEASES - Disclosed herein are substituted pyrrolopyridine and pyrrolopyrazine compounds and compositions useful in the treatment of TAK mediated diseases, such as cancer, having the structure of Formula (I): | 2015-07-30 |
20150210706 | Benzodiazepine Bromodomain Inhibitor - The present invention relates to a benzodiazepine compound, processes for its preparation, pharmaceutical compositions containing such a compound and to its use in therapy. | 2015-07-30 |
20150210707 | Crystals of Dispiropyrrolidine Derivatives - Crystals of a dispiropyrrolidine compound or a salt thereof which inhibits the action of Mdm2 are provided. The present invention provides crystals of (3′R,4′S,5′R)-N-[(3R,6S)-6-carbamoyltetrahydro-2H-pyran-3-yl]-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide or a salt thereof which inhibits Mdm2 and has anti-tumor activity. The present invention also provides a medicament comprising the same. | 2015-07-30 |
20150210708 | NOVEL TRICYCLIC COMPOUNDS - The invention provides a compound of Formula (I) | 2015-07-30 |
20150210709 | 4-OXO-3,5,7,8-TETRAHYDRO-4H-PYRANO[4,3-D]PYRMINIDINYL COMPOUNDS FOR USE AS TANKYRASE INHIBITORS - The present invention provides for compounds of formula (I) | 2015-07-30 |
20150210710 | SPIROCYCLIC DERIVATIVES AS ANTIPARASITIC AGENTS - The invention recites spirocyclic derivatives of Formula (V.1) or (V.2), stereoisomers thereof, veterinary acceptable salts thereof, compositions thereof, processes for making, and their use as a parasiticide for an animal. The variables A, B, V, Z, Y, W | 2015-07-30 |
20150210711 | HEXAHYDRODIBENZO[A,G]QUINOLIZINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF - The present invention relates to a novel hexahydrodibenzo[a,g]quinoline compound represented by general formula (I) and its derivatives, enantiomer, diastereoisomer, raceme and mixtures thereof, as well as pharmaceutically acceptable salts thereof. The present invention further relates to a method for preparing the compound, and the compound has good prevention and treatment effect on neurological diseases, especially diseases associated with dopamine receptor and 5-hydroxytryptamine receptor. The bioactivity experiment demonstrates that, the compound is expected to be developed into a novel and potent chemical entity for treating diseases associated with dopamine receptor and 5-hydroxytryptamine receptor, especially schizophrenia, Parkinson's disease, drug addiction, migraine and so on. | 2015-07-30 |
20150210712 | Prodrugs of Secondary Amine Compounds - The present invention relates to compounds of Formula I: | 2015-07-30 |
20150210713 | GRISEOFULVIN DERIVATIVES - The present invention relates to compounds of the following general formula (I), or to a pharmaceutically acceptable salt thereof, as well as to the uses thereof as a drug, in particular in the treatment of cancerous or precancerous hyperproliferative conditions, and to the pharmaceutical compositions containing same. | 2015-07-30 |
20150210714 | NOVEL RAPAMYCIN ANALOGUE - There is provided inter alia a compound of formula (I) or a pharmaceutically acceptable salt thereof and its use in therapy. | 2015-07-30 |
20150210715 | 5,5-HETEROAROMATIC ANTI-INFECTIVE COMPOUNDS - The invention provides a series of 5,5-heteroaromatic compounds, syntheses thereof, compositions thereof, and methods of using such compounds and compositions. Various embodiments provide methods of killing and/or inhibiting the growth of | 2015-07-30 |
20150210716 | BACE INHIBITORS - The present invention provides a compound of Formula III: | 2015-07-30 |
20150210717 | SPECIFIC INHIBITORS OF PROTEIN P21 AS THERAPEUTIC AGENTS - The present invention relates to novel inhibitors of p21. These inhibitors are useful as therapeutic agents for promot ing cell regeneration and in the treatment of cancer. Improvement of cell regeneration is particularly desirable in patients of old age or in patients suffering from chronic diseases, acute or chronic injuries. | 2015-07-30 |
20150210718 | MACROCYCLIC COMPOUNDS AND METHODS OF TREATMENT - The instant invention describes macrocyclic compounds having therapeutic activity, and methods of treating disorders such as cancer, tumors and cell proliferation related disorders, and HDAC mediated disorders. | 2015-07-30 |
20150210719 | ANTIBACTERIAL COMPOUNDS - The present invention is related to novel compounds of formula (I) that may inhibit the activity of the FabI enzyme, and which are useful in the treatment of bacterial infections. It further relates to pharmaceutical compositions comprising these compounds, and chemical processes for preparing these compounds. | 2015-07-30 |
20150210720 | FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE - Compounds of formula (I) | 2015-07-30 |
20150210721 | SILANE COUPLING AGENT, MAKING METHOD, PRIMER COMPOSITION, AND COATING COMPOSITION - A silane coupling agent is obtained from high-temperature heat distillation reaction of a silane coupling agent having a customary amic acid structure group. Dealcoholization reaction takes place between the carboxylic acid group and the alkoxysilyl group in the structure to induce intramolecular crosslinking. The crosslinked polymer component exerts a remarkable adhesion promoting effect. | 2015-07-30 |
20150210722 | KINASE INHIBITORS - There are provided compounds of formula (I), | 2015-07-30 |
20150210723 | Low Volatile Amine Salts of Anionic Pesticides - The present invention relates to a salt comprising an anionic pesticide and a cationic polyamine of the formula (A) or (B) as described in the description. The invention further relates to an agrochemical composition comprising said salt. It also relates to a method for preparing said salt comprising combining the pesticide in its neutral form or as salt, and the polyamine in its neutral form or as salt. In addition, the invention relates to a method of combating harmful insects and/or phytopathogenic fungi. It also relates to a method of controlling undesired vegetation. Finally, the invention relates to seed comprising said salt. | 2015-07-30 |
20150210724 | MORPHIC FORMS OF HEXADECYLOXYPROPYL-PHOSPHONATE ESTERS AND METHODS OF SYNTHESIS THEREOF - The disclosure describes methods of synthesis of phosphonate ester compounds. The methods according to the disclosure allow for large-scale preparation of phosphonate ester compounds having high purity and stability. Also disclosed are morphic forms of phosphonate ester compounds. | 2015-07-30 |
20150210725 | PROCESS FOR PREPARATION OF ARYL PHOSPHOROUS COMPOUNDS - The present invention relates to cost effective, transition-metal-free one pot process for the preparation of aryl phosphorous compounds of formula (I). Particularly, the present invention provides a process for C—P bond formation. In particular, the invention relates to mild fluoride induced generation of aryne species in situ which allows P—C bond formation to obtain aryl phosphorous compounds of formula (I) under mild condition. | 2015-07-30 |
20150210726 | Methods for Preparing Ruthenium Carbene Complex Precursors and Ruthenium Carbene Complexes - A method for preparing a ruthenium carbene complex precursor includes reacting a ruthenium refinery salt with a hydrogen halide to form a ruthenium intermediate, and reacting the ruthenium intermediate with an L-type ligand to form the ruthenium carbene complex precursor. A method for preparing a ruthenium vinylcarbene complex includes converting a ruthenium carbene complex precursor into a ruthenium hydrido halide complex, and reacting the ruthenium hydrido halide complex with a propargyl halide to form the ruthenium vinylcarbene complex. A method for preparing a ruthenium carbene complex includes converting a ruthenium carbene complex precursor into a ruthenium carbene complex having a structure (PR | 2015-07-30 |
20150210727 | COMPOUNDS AND METHODS FOR TREATING MAMMALIAN GASTROINTESTINAL MICROBIAL INFECTIONS - Disclosed are compounds and pharmaceutically acceptable salts thereof, which are useful as inhibitors of IMPDH. In certain embodiments, a compound selectively inhibits a parasitic IMPDH versus a host IMPDH. Also disclosed are pharmaceutical compositions comprising one or more compounds of the invention. Related methods of treating various parasitic and bacterial infections in mammals are disclosed. Moreover, the compounds may be used alone or in combination with other therapeutic or prophylactic agents, such as anti-virals, anti-inflammatory agents, antimicrobials and immunosuppressants. | 2015-07-30 |
20150210728 | GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS - This invention relates to carbamate-containing or thiocarbamate-containing galacto-pyranosyl compounds useful as therapeutic agents and being represented by the structural formula (II), wherein: X is O or S, R is selected from the group consisting of C | 2015-07-30 |
20150210729 | MACROLIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF - The patent application relates to compounds of formula (I) below: | 2015-07-30 |
20150210730 | CERTAIN COMPOUNDS, COMPOSITIONS AND METHODS - The present invention provides certain tetrahydrouridine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of making and using such compounds. | 2015-07-30 |
20150210731 | MONOMER FOR SYNTHESIS OF RNA, METHOD FOR PRODUCING SAME, AND METHOD FOR PRODUCING RNA - The objective of the present invention is to provide a monomer for RNA synthesis which can be efficiently produced and therefore by which the producing cost of RNA can be remarkably decreased, and a method for efficiently producing the monomer in a small number of steps. In addition, the objective of the present invention is also to provide a method by which RNA can be efficiently produced even when a approximately stoichiometry amount of the monomer for RNA synthesis is used. The monomer for RNA synthesis according to the present invention is represented by the following formula (I) or (I′): | 2015-07-30 |
20150210732 | METHODS OF FUNCTIONALIZATION AND REAGENTS USED IN SUCH METHODS USING AN AZA-ISATOIC ANHYDRIDE OR A DERIVATIVE THEREOF, BIOLOGICAL MOLECULES THUS TREATED AND KITS - The present invention relates to a method of functionalization of at least one ribonucleic acid (RNA) molecule, contained in a liquid sample, which includes the following steps: a) providing at least: one binding molecule consisting of an aza-isatoic anhydride or a derivative thereof, one group of interest, and one linkage joining the binding molecule to the group of interest, b) reacting the anhydride function of the binding molecule with at least one hydroxyl group carried: in position 2′ of the ribose of one of the RNA nucleotides, and/or in position(s) 2′ and/or 3′ of the ribose of the nucleotide at the terminal 3′ end of the RNA, and obtaining an aza-anthranilate that joins, by means of the linkage, the RNA to the group of interest. | 2015-07-30 |
20150210733 | NUCLEIC ACID CHEMICAL MODIFICATIONS - The present invention provides nucleosides of formula (1) and oligonucleotides comprising at least on nucleoside of formula (2): | 2015-07-30 |
20150210734 | 3-SUBSTITUTED ESTRA-1,3,5(10),16-TETRAENE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS CONTAINING SAME, AND USE THEREOF FOR THE PRODUCTION OF MEDICAMENTS - The invention relates to AKR1C3 inhibitors and to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular bleeding disorders and endometriosis. | 2015-07-30 |
20150210735 | Isolation and Purification of Antibodies Using Protein A Affinity Chromatography - Disclosed herein are methods for the isolation and purification of antibodies wherein the use of an affinity chromatographic step results in an antibody composition sufficiently pure for pharmaceutical uses. The methods described herein comprise pH viral reduction/inactivation, ultrafiltration/diafiltration, affinity chromatography, preferably Protein A affinity, ion exchange chromatography, and hydrophobic chromatography. Further, the present invention is directed toward pharmaceutical compositions comprising one or more antibodies of the present invention. | 2015-07-30 |
20150210736 | METHOD OF RECOVERING PEPTIDE AND METHOD OF DETETING PEPTIDE - Disclosed is a method of recovering a peptide including: mixing a liquid sample containing a complex of peptide and protein in blood with a reagent containing at least one selected from the group consisting of Zn | 2015-07-30 |
20150210737 | INTEGRATED PROCESS FOR THE PRODUCTION OF THERAPEUTICS (HUMAN ALBUMIN, INTRAVENOUS IMMUNOGLOBULINS, CLOTTING FACTOR VIII AND CLOTTING FACTOR IX) FROM HUMAN PLASMA - The invention relates to an integrated scheme for fractionation and purification of plasma products (human albumin, intravenous immunoglobulin (IVIG), clotting factor VIII and clotting factor IX) by sequential chromatography and virus reduction steps. The therapeutically administrable protein IVIG has purity levels exceeding 98%, aggregates and dimers at less than 0.2%, Fc function of >90% and anti-complementary activity of less than 0.5 CH | 2015-07-30 |
20150210738 | MOLECULAR SLEDS AND USES THEREOF - The present invention relates to compositions which may comprise a molecular sled linked to cargo and uses thereof. In particular, the present invention relates to a non-naturally occurring or engineered composition which may comprise a molecular sled, linkers and a molecular cargo connected to the sled via the linkers. Methods involving the use of molecular sleds and their cargoes and pharmaceutical compositions, methods for treating treating cancer, a degenerative disease, a genetic disease or an infectious disease as well as diagnostic methods are also contemplated by the present invention. | 2015-07-30 |
20150210739 | AZAHETEROCYCLES AS BIR2 AND/OR BIR3 INHIBITORS - Disclosed are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein R | 2015-07-30 |
20150210740 | PSEUDOURIDIMYCIN (PUM) AND ITS DERIVATIVES - The present invention relates to novel compounds of formula (I) and pharmaceutically acceptable salts thereof, a process for the preparation thereof, as well as pharmaceutical compositions containing them and the use thereof as drugs, particularly for the treatment of infectious diseases. | 2015-07-30 |
20150210741 | JAGARICIN DERIVATIVES AND THEIR USE AS FUNGICIDE OR ANTITUMOR AGENT - This invention concerns a novel compound termed jagaricin, jagaricin derivatives, pharmaceutical compositions comprising these compounds, a method for producing jagaricin, and the use of the novel compound as fungicide or antitumor agent. | 2015-07-30 |
20150210742 | NOVEL ALLERGEN FROM RAGWEED POLLEN AND USES THEREOF - The present invention notably concerns a novel major allergen from ragweed pollen, named Amb a X, as well as isoallergens and isoforms thereof. Fragments of the aforementioned polypeptides and homologous polypeptides, in particular homologous polypeptides in related plant species, also make part of the invention. The invention also concerns uses of said polypeptides, in particular for diagnosing and preventing or treating an allergy. | 2015-07-30 |
20150210743 | CHIMERIC INHIBITOR MOLECULES OF COMPLEMENT ACTIVATION - The present invention relates to novel chimeric molecules of ficolin-associated polypeptides, such as fusion polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases. The present invention further relates to nucleic acid molecules encoding such fusion polypeptides, vectors and host cells used in the production of the fusion polypeptides. | 2015-07-30 |
20150210744 | GLUCAGON ANALOGUES - The present invention relates to glucagon analogues and their medical use, for example in the treatment of hypoglycaemia. In particular, the present invention relates to stable glucagon analogues suitable for use in a liquid formulation. | 2015-07-30 |
20150210745 | Double-Acylated GLP-1 Derivatives with a Linker - The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 18 of GLP-1(7-37) (SEQ ID NO: 1), a second K residue at another position, and a maximum of twelve amino acid changes as compared to GLP-1(7-37); which derivative comprises two protracting moieties attached to said first and second K residue, respectively, via a linker, wherein the protracting moiety is selected from HOOC—(CH2)x-CO—*, and Chem. 1: HOOC—C6H4-0-(CH2)y-CO—*, Chem. 2: in which x is an integer in the range of 6-18, and y is an integer in the range of 3-17; and the linker comprises *—NH—(CH2)q-CH[(CH2)w-NH2]-CO—*, Chem. 3: wherein q is an integer in the range of 0-5, and w is an integer in the range of 0-5; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to the pharmaceutical use thereof, for example in the treatment and/or prevention of all forms of diabetes and related diseases, as well as to corresponding novel peptides and side chain intermediates. The derivatives are potent, protracted, and suitable for oral administration. | 2015-07-30 |
20150210746 | METHOD FOR EXPRESSION, EXTRACTION AND PURIFICATION OF SOLUBLE RECOMBINANT PROTEIN - The present invention relates to a method for expressing, extracting and refining recombinant human growth hormone (hGH). More particularly, the present invention relates to a method for the intracellular expression of a target protein with minimizing the formation of insoluble inclusion bodies during the mass production of the protein in | 2015-07-30 |
20150210747 | PROTEASE STABILIZED ACYLATED INSULIN ANALOGUES - Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H. | 2015-07-30 |
20150210748 | PROTEASE STABILIZED ACYLATED INSULIN ANALOGUES - Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H. | 2015-07-30 |
20150210749 | METHODS OF TREATMENT USING FUSION PROTEINS - The invention relates to method of treatment using fusion proteins. The fusion proteins may be RAGE fusion proteins produce by methods for controlling the glycosylation of the fusion protein. The fusion protein may comprise a RAGE polypeptide linked to an immunoglobulin polypeptide. | 2015-07-30 |
20150210750 | PERFUSION MEDIA - Perfusion media are disclosed providing excellent cell density, titer and product quality for production of a therapeutic protein in a perfusion process. | 2015-07-30 |
20150210751 | Method and Composition for Crystallizing G Protein-Coupled Receptors - Certain embodiments provide a method for crystallizing a GPCR. The method may employ a fusion protein comprising: a) a first portion of a G-protein coupled receptor (GPCR), where the first portion comprises the TM1, TM2, TM3, TM4 and TM5 regions of the GPCR; b) a stable, folded protein insertion; and c) a second portion of the GPCR, where the second portion comprises the TM6 and TM7 regions of the GPCR. | 2015-07-30 |
20150210752 | ALBUMIN VARIANTS - The present invention relates to variants of a parent albumin, the variants having altered plasma half-life compared with the parent albumin. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants. | 2015-07-30 |
20150210753 | GLYCOPROTEINS WITH ANTI-INFLAMMATORY PROPERTIES - Glycoproteins having particular sialylation patterns, and methods of making and using such glycoproteins, are described. | 2015-07-30 |
20150210754 | IMMUNOGLOBULIN REDUCED IN THROMBOGENIC AGENTS AND PREPARATION THEREOF - The invention relates to an immunoglobulin composition reduced in thrombogenic agents and to methods for its preparation. One method comprises subjecting an immunoglobulin containing solution to a negative cation exchanger chromatography at a pH in the range of higher than 3.8 to equal to or lower than 5.3. The solution can also be subjected to a negative anion exchanger chromatography at a pH in the range of 7 to 8.2. | 2015-07-30 |
20150210755 | ANTI-POLY-N-ACETYL GLUCOSAMINE (PNAG) MONOCLONAL ANTIBODY AND USES THEREOF FOR THE PREVENTION OR TREATMENT OF PNAG EXPRESSING BACTERIAL INFECTION - Provided are methods for the treatment or prevention of microbial infections (e.g., bacterial infection) in which the underlying pathology involves a PNAG-expressing microbe (e.g., PNAG-expressing bacteria). The methods of the invention generally involve administering to the subject an effective amount of an antibody that specifically binds to PNAG. Such methods are particularly useful for the treatment of nosocomial | 2015-07-30 |
20150210756 | COMPOSITIONS AND METHODS FOR PHAGOCYTE DELIVERY OF ANTI-STAPHYLOCOCCAL AGENTS - The present application generally relates to multi-specific molecules that bind to multiple bacterial virulence factors, methods for producing these binding molecules, and the use of these binding molecules to treat bacterial infections. In particular, the binding molecules comprise at least two binding domains, preferably an antibody or antibody fragment and an alternative scaffold. The first binding domain is capable of binding to a glycosylated staphylococcal surface protein, preferably an SDR-containing protein. The second binding domain is capable of binding to a staphylococcal leukotoxin, preferably LukAB, LukD or LukE. These multi-specific binding compounds have killing activity against staphylococci and, thus, can be used in the treatment and/or amelioration of a | 2015-07-30 |
20150210757 | POLYPEPTIDES AND IMMUNIZING COMPOSITIONS CONTAINING GRAM POSITIVE POLYPEPTIDES AND METHODS OF USE - The present invention provides isolated polypeptides isolatable from a | 2015-07-30 |
20150210758 | ANGIOPOIETIN-LIKE 4 ANTIBODY AND A METHOD OF ITS USE IN CANCER TREATMENT - An antibody that binds C terminal region of angiopoietin like 4 protein its use and methods of treating cancer with the same. | 2015-07-30 |
20150210759 | HUMAN ISLET AMYLOID POLYPEPTIDE (HIAPP) SPECIFIC ANTIBODIES AND USES THEREOF - Provided are novel human islet amyloid polypeptide, also known as amylin and IAPP and proIAPP respectively, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for IAPP and/or proIAPP are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for IAPP and/or proIAPP targeted immunotherapy and diagnostics, respectively. | 2015-07-30 |
20150210760 | THERAPEUTIC METHOD FOR PANCREATIC CANCER - The present invention relates to methods and medicarnents useful for treating locally advanced pancreatic cancer (LAPC). Improved therapeutic methods and regimens comprising anti-connective tissue growth factor (CTGF) agents, including anti-CTGF antibodies, are provided. Included are induction therapies for converting unreseetable LAPC into borderline or resectable status. | 2015-07-30 |
20150210761 | ANTIBODY SPECIFICALLY BINDING TO ANG2 AND USE THEREOF - An Ang2 specific antibody, a method of preventing and/or treating a disease related to the activation and/or overproduction (overexpression) of Ang2 by administering the antibody to a subject, and a method of screening a candidate substance for diagnosing, preventing, or treating a disease related to activation or overproduction of Ang2. | 2015-07-30 |
20150210762 | ENHANCEMENT OF TRANSPORT OF THERAPEUTIC MOLECULES ACROSS THE BLOOD BRAIN BARRIER - The invention is based, at least in part, on the finding that a dimeric version of a BBB-transmigrating antibody (e.g., the TMEM30A (CDC-50A) binding antibody, FC5) was found to greatly enhance transport across the BBB as compared to monovalent FC5 V | 2015-07-30 |
20150210763 | MODIFIED Fc REGION OF ANTIBODY - Polypeptides with improved stability as compared to that of a parent polypeptide were successfully obtained by modifying at least one amino acid in a loop region of the antibody Fc region. Furthermore, by combining multiple amino acid modifications in the loop region, polypeptides with maintained or enhanced FcγR-binding activity as well as improved thermal stability, polypeptides with decreased FcγR-binding activity as well as improved thermal stability, and polypeptides with not only improved thermal stability and adjusted FcγR-binding activity but also decreased aggregate content, as compared to those of a parent polypeptide, were successfully obtained. | 2015-07-30 |
20150210764 | BINDING PROTEINS AND METHODS OF USE THEREOF - The present disclosure provides binding proteins, such as antibodies, that bind beta klotho, including human beta klotho, and methods of their use. | 2015-07-30 |
20150210765 | Multivalent and Monovalent Multispecific Complexes and Their Uses - Compositions containing multivalent and monovalent multispecific complexes having scaffolds such as antibodies that support such binding functionalities are described. The use of and methods of compositions containing multivalent and monovalent multispecific complexes having scaffolds, such as antibodies, that support such binding functionalities are also described. | 2015-07-30 |
20150210766 | ANTI-HER3 SCFV FRAGMENT AND BISPECIFIC ANTI-C-MET/ANTI-HER3 ANTIBODIES COMPRISING THE SAME - Provided is an anti-Her3 antibody or antigen-binding fragment thereof, an anti-c-Met/anti-Her3 bispecific antibody including the same, and a method of preventing and/or treating a cancer using the same. | 2015-07-30 |
20150210767 | STABLE ANTI-TNFR1 POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS & ANTAGONISTS - The invention relates to storage-stable anti-TNFR1 antibody single variable domains (dAbs), antagonists and multispecific ligands, as well as methods and uses of these. The anti-TNFR1 polypeptides, antibody single variable domains (dAbs), antagonists and multispecific ligands are useful for treating and/or preventing inflammatory disease, such as arthritis or COPD, as well as for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient. | 2015-07-30 |
20150210768 | Methods and Compounds for Preventing, Treating and Diagnosing an Inflammatory Condition - Provided is an antibody with a specificity to an epitope that is a region corresponding to amino acid positions 63-79 or 73-85 of the human protein S100A9. Provided is further an antibody with a specificity to an epitope that is a region corresponding to amino acid positions 55-71 of the human protein S100A8. Provided is further the use of such antibody in the treatment or diagnosis of an inflammatory disorder. Also provided is an in-vitro method of identifying a compound capable of inhibiting the formation of a complex between a peptide corresponding to one of the above epitopes of S100A9 or the above epitope of S100A8 and a TLR4 receptor, where a compound suspected to affect the complex formation is contacted with the peptide and the TLR4 receptor. Further provided is an in-vitro method of identifying a compound capable of increasing the stability of a complex between a S100A8 protein and a S100A9 protein, where the two proteins are contacted in the presence of a compound suspected to affect the complex formation. | 2015-07-30 |
20150210769 | ANTIBODY MOLECULES TO PD-1 AND USES THEREOF - Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders. | 2015-07-30 |
20150210770 | THERAPEUTIC AND DIAGNOSTIC TARGET - The present disclosure provides methods and compositions for treatment, screening, diagnosis and prognosis of cancer, such as bladder cancer, esophagus cancer, head and neck cancer, lung cancer, pancreatic cancer, gastric cancer, uterine cancer, cervical cancer, skin cancer and breast cancer, for monitoring the effectiveness of cancer, such as bladder cancer, esophagus cancer, head and neck cancer, lung cancer, pancreatic cancer, gastric cancer, uterine cancer, cervical cancer, skin cancer and breast cancer treatment, and for drug development. | 2015-07-30 |
20150210771 | TREATMENT OF BRAIN CANCERS USING CENTRAL NERVOUS SYSTEM MEDIATED GENE TRANSFER OF MONOCLONAL ANTIBODIES - The invention provides methods to inhibit or treat brain cancers by locally inhibiting expression or activity of growth factors or growth factor receptors. | 2015-07-30 |
20150210772 | METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND AN ANTI-CD20 ANTIBODY - The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an anti-CD20 antibody and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer. | 2015-07-30 |